BioGaia AB (publ) (FRA:BGLA)

Germany flag Germany · Delayed Price · Currency is EUR
10.40
-0.03 (-0.29%)
At close: Jan 30, 2026
0.78%
Market Cap1.05B +9.5%
Revenue (ttm)132.28M +7.9%
Net Income28.57M -6.2%
EPS0.28 -6.4%
Shares Outn/a
PE Ratio36.83
Forward PE28.72
Dividend0.63 (5.99%)
Ex-Dividend DateMay 8, 2025
Volumen/a
Average Volume21
Open10.40
Previous Close10.43
Day's Range10.40 - 10.40
52-Week Range8.38 - 12.00
Betan/a
RSI60.09
Earnings DateFeb 12, 2026

About BioGaia AB

BioGaia AB (publ), a healthcare company, develops, manufactures, markets and sells probiotic products for gut, oral, and immune health in Europe, the Middle East, Africa, the United States, the Asia-Pacific, Australia, and New Zealand. It operates through Pediatrics, Adult Health, and Other segments. The Pediatrics segment offers drops, oral rehydration solutions, and gut health tablets, as well as cultures that are used as an ingredient in infant formula and milk formula. The Adult Health segment provides gut health tablets, bone health tablet... [Read more]

Industry Pharmaceutical Preparations
Founded 1990
Employees 238
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol BGLA
Full Company Profile

Financial Performance

In 2024, BioGaia AB's revenue was 1.42 billion, an increase of 9.73% compared to the previous year's 1.30 billion. Earnings were 351.39 million, a decrease of -3.82%.

Financial numbers in SEK Financial Statements